202 related articles for article (PubMed ID: 25406657)
1. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
Naiker S; Connolly C; Wiesner L; Kellerman T; Reddy T; Harries A; McIlleron H; Lienhardt C; Pym A
BMC Pharmacol Toxicol; 2014 Nov; 15():61. PubMed ID: 25406657
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients.
Kouanda S; Ouedraogo HG; Cisse K; Compaoré TR; Sulis G; Diagbouga S; Roggi A; Tarnagda G; Villani P; Sangare L; Simporé J; Regazzi M; Matteelli A
BMC Infect Dis; 2020 Jun; 20(1):449. PubMed ID: 32590942
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week.
Ouedraogo HG; Matteelli A; Sulis G; Compaore TR; Diagbouga S; Tiendrebeogo S; Roggi A; Cisse K; Giorgetti PF; Villani P; Sangare L; Simpore J; Regazzi M; Kouanda S
Ann Clin Microbiol Antimicrob; 2020 Jan; 19(1):3. PubMed ID: 31969147
[TBL] [Abstract][Full Text] [Related]
4. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.
Lan NT; Thu NT; Barrail-Tran A; Duc NH; Lan NN; Laureillard D; Lien TT; Borand L; Quillet C; Connolly C; Lagarde D; Pym A; Lienhardt C; Dung NH; Taburet AM; Harries AD
PLoS One; 2014; 9(1):e84866. PubMed ID: 24465443
[TBL] [Abstract][Full Text] [Related]
5. Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.
Kendall MA; Lalloo U; Fletcher CV; Wu X; Podany AT; Cardoso SW; Ive P; Benson CA
Clin Infect Dis; 2021 Aug; 73(4):706-715. PubMed ID: 34398956
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients.
Ramachandran G; Hemanth Kumar AK; Kannan T; Sridhar R; Guha SK; Kadam D; Poorana Gangadevi N; Rajapandian T
Indian J Tuberc; 2019 Jan; 66(1):129-133. PubMed ID: 30797270
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.
Moultrie H; McIlleron H; Sawry S; Kellermann T; Wiesner L; Kindra G; Gous H; Van Rie A
J Antimicrob Chemother; 2015 Feb; 70(2):543-9. PubMed ID: 25281400
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
[TBL] [Abstract][Full Text] [Related]
9. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
Murphy RA; Marconi VC; Gandhi RT; Kuritzkes DR; Sunpath H
PLoS One; 2012; 7(9):e44793. PubMed ID: 23028623
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART.
Rawizza HE; Darin KM; Oladokun R; Brown B; Ogunbosi B; David N; Akanmu S; Olaitan O; Chang C; Scarsi KK; Okonkwo P; Kanki PJ
J Antimicrob Chemother; 2019 Sep; 74(9):2707-2715. PubMed ID: 31139825
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India.
Ramachandran G; Bhavani PK; Hemanth Kumar AK; Srinivasan R; Raja K; Sudha V; Venkatesh S; Chandrasekaran C; Swaminathan S
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1564-8. PubMed ID: 24200269
[TBL] [Abstract][Full Text] [Related]
13. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?
Loeliger A; Suthar AB; Ripin D; Glaziou P; O'Brien M; Renaud-Thery F; Crowley S; Williams B; Ridzon R; Granich R; Gilks C
Int J Tuberc Lung Dis; 2012 Jan; 16(1):6-15. PubMed ID: 21819645
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.
Weiner M; Benator D; Peloquin CA; Burman W; Vernon A; Engle M; Khan A; Zhao Z;
Clin Infect Dis; 2005 Nov; 41(9):1343-9. PubMed ID: 16206114
[TBL] [Abstract][Full Text] [Related]
15. Improved tuberculosis outcomes with daily vs. intermittent rifabutin in HIV-TB coinfected patients in India.
Jenks JD; Kumarasamy N; Ezhilarasi C; Poongulali S; Ambrose P; Yepthomi T; Devaraj C; Benson CA
Int J Tuberc Lung Dis; 2016 Sep; 20(9):1181-4. PubMed ID: 27510243
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis.
Boulanger C; Rolla V; Al-Shaer MH; Peloquin C
Int J Antimicrob Agents; 2020 Feb; 55(2):105840. PubMed ID: 31704214
[TBL] [Abstract][Full Text] [Related]
17. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
Zhang J; Zhu L; Stonier M; Coumbis J; Xu X; Wu Y; Arikan D; Farajallah A; Bertz R
J Antimicrob Chemother; 2011 Sep; 66(9):2075-82. PubMed ID: 21712242
[TBL] [Abstract][Full Text] [Related]
18. The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.
Decloedt EH; Maartens G; Smith P; Merry C; Bango F; McIlleron H
PLoS One; 2012; 7(3):e32173. PubMed ID: 22412856
[TBL] [Abstract][Full Text] [Related]
19. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
20. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Weiner M; Benator D; Burman W; Peloquin CA; Khan A; Vernon A; Jones B; Silva-Trigo C; Zhao Z; Hodge T;
Clin Infect Dis; 2005 May; 40(10):1481-91. PubMed ID: 15844071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
